Physician profile
Rafael Blanco
NPI 1164474615
$16,871.90
in general payments reported to CMS, 2019-2025
68 companies · $2,432 in 2025
The $2,432 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,117 · 2020: $965 · 2021: $1,814 · 2022: $3,120 · 2023: $3,286 · 2024: $3,137 · 2025: $2,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,913 · Long Term Medical Supply Or Device Loan: $698 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,912.88 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $244.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,627.23 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $1,612.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,111.61 | 2019-2025 | Calquence |
| Lilly USA, LLC | $973.54 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $803.84 | 2021-2025 | Enhertu, Datroway |
| Genzyme Corporation | $776.39 | 2019-2023 | |
| Gilead Sciences, INC. | $770.13 | 2022-2025 | Trodelvy |
| Celgene Corporation | $657.26 | 2019-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $558.67 | 2019-2025 | Darzalex, Rybrevant, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $489.99 | 2019-2024 | |
| Pfizer INC. | $477.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $474.38 | 2019-2025 | Keytruda, Lynparza |
| Exelixis INC. | $455.32 | 2019-2025 | Cabometyx |
| Abbvie INC. | $413.94 | 2021-2025 | Venclexta |
| Tesaro, INC. | $379.80 | 2019 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $377.32 | 2019-2023 | Adcetris, Padcev, Tivdak |
| Amgen INC. | $336.72 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $319.61 | 2023-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $289.23 | 2019-2023 | Tazverik, Somatuline Depot, Onivyde |
| Kite Pharma, INC. | $276.20 | 2020-2023 | Yescarta |
| Glaxosmithkline, LLC. | $274.41 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $259.82 | 2019-2022 | |
| Eisai INC. | $243.34 | 2022-2025 | |
| Astellas Pharma US INC | $218.47 | 2023-2025 | Padcev, Vyloy, Xospata |
| Incyte Corporation | $203.21 | 2019-2025 | Jakafi, Monjuvi |
| Jazz Pharmaceuticals INC. | $196.82 | 2022-2025 | |
| Puma Biotechnology, INC. | $196.32 | 2019-2025 | |
| Sirtex Medical INC | $177.00 | 2019-2022 | |
| Beigene USA, INC. | $142.77 | 2021-2024 | Brukinsa, Tevimbra |
| Sanofi US Services INC. | $131.90 | 2025 | |
| Array Biopharma INC | $118.97 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Penumbra, INC. | $112.39 | 2024 | Indigo System |
| Lexicon Pharmaceuticals, INC. | $112.18 | 2019 | |
| Mirati Therapeutics, INC. | $108.54 | 2023-2024 | Krazati |
| Epizyme, INC. | $108.47 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $105.55 | 2022-2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $86.70 | 2022-2025 | Fotivda |
| Karyopharm Therapeutics INC. | $60.44 | 2020-2023 | Xpovio |
| Inari Medical, INC. | $57.86 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Tersera Therapeutics LLC | $55.18 | 2025 | Zoladex |
| Pharmacosmos Therapeutics INC. | $55.09 | 2023-2025 | Monoferric |
| Legend Biotech USA INC. | $52.00 | 2024-2025 | Carvykti |
| Beone Medicines USA, INC. | $50.75 | 2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $50.53 | 2022 | |
| Csl Behring | $36.28 | 2022-2023 | Afstyla, Idelvion |
| Sumitomo Pharma America, INC. | $34.99 | 2024-2025 | Orgovyx |
| Emd Serono, INC. | $31.52 | 2019-2025 | |
| Deciphera Pharmaceuticals INC. | $30.44 | 2021-2022 | |
| Myovant Sciences INC. | $29.86 | 2022 | |
| Taiho Oncology, INC. | $29.27 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $28.58 | 2020 | |
| Pharmaessentia USA Corporation | $26.69 | 2025 | Besremi |
| Tempus Ai, INC | $24.88 | 2024 | Xt Cdx |
| Telix Pharmaceuticals | $24.57 | 2023 | Illuccix |
| Dendreon Pharmaceuticals LLC | $23.00 | 2022 | |
| Servier Pharmaceuticals LLC | $22.53 | 2024 | |
| Genmab U.S., INC. | $22.18 | 2024 | Epkinly |
| Amag Pharmaceuticals, INC. | $21.46 | 2019 | |
| Ge Healthcare | $20.07 | 2022 | |
| Morphosys, US INC. | $17.21 | 2023 | Monjuvi |
| Tg Therapeutics, INC. | $14.32 | 2021 | |
| Agios Pharmaceuticals, INC. | $12.99 | 2021 | |
| Adc Therapeutics America, INC. | $12.50 | 2022 | |
| Blueprint Medicines Corporation | $11.85 | 2020 | |
| Alexion Pharmaceuticals, INC. | $11.12 | 2019 | |
| Secura Bio, INC. | $10.06 | 2022 | |
| Clovis Oncology, INC. | $9.88 | 2020 | |
| Rigel Pharmaceuticals, INC. | $5.42 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.